As of close of business last night, Redhill Biopharma Ltd. ADR’s stock clocked out at $0.50, down -4.93% from its previous closing price of $0.53. In other words, the price has decreased by -$0.0226 from its previous closing price. On the day, 857513 shares were traded.
Ratios:
To gain a deeper understanding of RDHL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.78 and its Current Ratio is at 0.96. In the meantime, Its Debt-to-Equity ratio is 0.66 whereas as Long-Term Debt/Eq ratio is at 0.29.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on August 31, 2021, initiated with a Overweight rating and assigned the stock a target price of $22.
On May 18, 2021, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $23.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RDHL now has a Market Capitalization of 14.96M and an Enterprise Value of 10.23M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.42 while its Price-to-Book (P/B) ratio in mrq is 0.57. Its current Enterprise Value per Revenue stands at 0.29 whereas that against EBITDA is 0.19.
Stock Price History:
Over the past 52 weeks, RDHL has reached a high of $5.91, while it has fallen to a 52-week low of $0.26. The 50-Day Moving Average of the stock is 0.6717, while the 200-Day Moving Average is calculated to be 0.9549.
Shares Statistics:
It appears that RDHL traded 1.75M shares on average per day over the past three months and 664.37k shares per day over the past ten days. A total of 29.70M shares are outstanding, with a floating share count of 29.55M. Insiders hold about 0.50% of the company’s shares, while institutions hold 6.70% stake in the company. Shares short for RDHL as of Feb 29, 2024 were 376.15k with a Short Ratio of 0.22, compared to 1.11M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.27% and a Short% of Float of 1.27%.
Earnings Estimates
As of right now, 0 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was -$0.5. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.
Revenue Estimates
In the current quarter, 2 analysts expect revenue to total $17.55M. It ranges from a high estimate of $23.98M to a low estimate of $18.5M. As of the current estimate, Redhill Biopharma Ltd. ADR’s year-ago sales were $21.61M, an estimated decrease of -18.80% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $12.8M, a decrease of -42.00% less than the figure of -$18.80% in the same quarter last year. There is a high estimate of $18.1M for the next quarter, whereas the lowest estimate is $18.1M.
